How stem cells are changing the face of medicine

published 26 July 2019

DNA filled liquid being injected into an egg cell nucleus © iStockphotos — Stem cells are a blank canvas that can develop into any type of cell, curing many diseases

Most cells in the human body are particular to one type of organ or function: skin cells, liver cells, or heart-muscle cells, for instance. Stem cells, however, are essentially a blank canvas that can develop into any type of cell. This in turn gives them vast life-saving potential, as a recent project at Imperial College London illustrates. Researchers grew stem cells in a gel and managed to transform them into patches of heart muscle measuring three by two centimetres. These patches could be used to strengthen the heart muscle in patients who have just had a heart attack. This technique would be a major breakthrough, since heart failure affects nearly one million people in Britain alone and the only way of reversing the damage caused by a heart attack is by carrying out a full heart transplant.

Only a few years ago there was only one source of stem cells: embryos that had been donated or aborted for research. This ethically fraught situation can now be avoided thanks to a technological breakthrough recognised by the award of the 2012 Nobel Prize for Medicine to Sir John Gurdon of the UK and Shinya Yamanaka of Japan. They discovered that mature, specialised cells that is, the normal cells that make up our body can be reprogrammed to become immature stem cells that is, ones capable of developing into any tissue of the body. For example, human skin cells can be reprogrammed to become stem cells, and then form nerve cells, or heart muscle cells and so on. This discovery caused textbooks to be rewritten and has created new opportunities to study diseases and develop new methods for diagnosis and effective therapy. These reprogrammed cells are called induced pluripotent stem cells (iPSCs) and, together with embryonic and umbilical-cord blood cells, comprise the three main types of stem cell capable of developing into other cells.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

There are some extraordinary examples of lives being saved by bone-marrow transplants. The procedure involves removing the patient's stem cells and replacing them with stem cells from a matching donor. These then attach themselves to the patient's bone marrow and start making new blood cells. (The donor's transplanted bone marrow is replaced by the donor's body in four to six weeks.) A few years ago a radiographer at Sheffield hospital who had joined the bone-marrow registry was told she was a match for a nine-year-old boy in Chile with a rare form of leukaemia whose only hope of survival was a bone-marrow transplant. She agreed to donate and his life was saved. Since up to 70% of patients with leukaemia or lymphoma do not have a match within their family, lives are saved by finding someone else who is a match.

The alternative to bone-marrow transplants is the use of umbilical-cord blood containing haematopoietic stem cells, immature blood-forming cells found in blood and bone marrow. These cells change into the red or white blood cells and platelets your body needs to remain healthy. In patients with bone-marrow disease this process doesn't work properly and cord blood is a potential source of the replacement tissue needed by patients with bone-marrow disease or those who contract leukaemia, lymphoma, or certain disorders of the blood and immune systems such as sickle-cell disease. The first successful cord blood transplant was carried out on a boy in 1988 and since then more than 25,000 such transplants have taken place worldwide on patients using matching cord blood from a blood bank.

Some parents arrange to have their baby's cord blood cryogenically preserved so that, should the baby contract blood cancer later on, its own cord blood is available for treatment. This means the cord blood is a perfect match rather than the close match hopefully achieved from a blood bank. This is a key consideration for ethnic-minority groups, for whom cord blood banks may have few donors so patients may be unable to find a match.

The FDA has approved several firms to begin clinical trials of promising stem-cell therapies. In the US there are 18 phase-III clinical trials of stem-cell treatments in progress and funded by the industry. Phase III is the third and final stage of clinical trials before a drug is submitted for approval. The conditions being treated are multiple myeloma, leukaemia, Crohn's disease, heart failure and colorectal cancer. A further 60 active stem-cell projects are in earlier stages of clinical trials. Some research focuses on drugs that treat any complications arising from stem-cell treatment.

The small US firm BrainStorm Cell Therapeutics concentrates on stem-cell treatments for neurological diseases. The company has developed a platform called NurOwn that can harvest stem cells from a patient's bone marrow and use them to produce the necessary quantities of modified stem cells to act against neurodegenerative diseases. BrainStorm has one phase-III clinical trial enrolling patients for progressive motor neurone disease. There is no cure and most patients only live for three to ten years after diagnosis (Stephen Hawking famously lived on for much longer). The group also has a phase-II trial for progressive multiple sclerosis and pre-clinical studies for Parkinson's and Huntingdon's diseases, all using its NurOwn platform.

Fate Therapeutics is a larger company concentrating on treatments for cancer. It uses pluripotent stem cells (iPSCs , the discovery of which was acknowledged by the 2012 Nobel prize) to make immunotherapies to target cancers. It has clinical trials in progress on treatments for both blood cancers and solid tumours. Fate has entered into collaborations with Ono Pharmaceutical and Juno Therapeutics (acquired by biopharma giant Celgene in early 2018; Celgene is at present being acquired by Bristol-Myers Squibb).

Stem-cell treatments are still in the early stages so investment in pure stem-cell companies is bound to be risky. Since the US is the clear world leader in biotech, we inevitably focus mainly on American companies. The three main options are to invest in a stem-cell therapy company (usually relatively small); in a larger biotech company that has some stem-cell activities; or in a "picks-and-shovels" company, that is, one that provides equipment and consumables needed by firms involved in stem-cell research and development.

Some large pharmaceutical and biotech companies have small stem-cell activities, but these are not yet significant in revenue or profit terms. Examples are Fate's collaboration with Ono Pharma and Smith & Nephew's $660m acquisition of Canada's Osiris Therapeutics, which produces a drug for GvHD. Investors are more likely to benefit from Big Biopharma through investments in medium-sized stem-cell companies that prove to be the recipients of bids after the publication of encouraging late-phase clinical trial results.

Typical medium-sized companies involved in stem-cell research of some kind include Fate Therapeutics and Sangamo Therapeutics, with market values around $1.3bn; Vericel and Mesoblast, in the range of $500m to $900m; Athersys & Cellular Biomedicine Group, worth between $200m to $300m; and BrainStorm Cell Therapeutics, with a market capitalisation of $100m. All these companies made a loss in 2018 and all had modest or negligible revenues. Only Fate and Sangamo had net cash of more than $100m at the end of the year; Sangamo had $400m and Fate $185m.

In assessing this type of company for investment, the quality of the pipeline and the presence of big biopharmaceutical partnerships are two key factors. The quality of the pipeline is important when a company needs to raise more funds, as most of them will need to do before their lead drugs can complete phase-III trials, gain approval and be launched on the market to bring in reliable cash flows. Big biopharmaceutical partnerships are invaluable for accessing US and world markets and therefore growing revenues rapidly.

The main risk for these early stage companies is the failure of a late-stage clinical trial. That can lead to a sharp share-price fall, just as a successful result, particularly for a phase-III trial, can lead to a sharp rise. The share-price fall will be catastrophic if the company only has one or two late-stage pipeline options and one or both of these fails. We now briefly describe the clinical pipelines of several medium-sized stem-cell biotechs.

Fate Therapeutics has one candidate FT500 in early clinical trials against solid tumours and four other candidates at the pre-clinical stage. FT500 is the first iPSC-derived cell line approved by the FDA for trials. Fate collaborates with Ono Pharma and Celgene. Sangamo has collaborations with Gilead, Pfizer, Sanofi and Shire, and has projects in gene therapy and gene editing as well as cell therapy.It has five clinical trials in progress, but these are in phases I and II.

Vericel has two cell-therapy products marketed in the US one for treating cartilage defects in the knee and the other for permanent skin replacement for serious deep burns. Revenues of $91m were recorded for 2018. The company has an exclusive licence agreement with MediWound, a small biotech that specialises in wound and burn care, and is looking for partners to market its products outside the US. Three clinical trials are in progress on cartilage repair and treatments for severe burns. It reduced its losses to $2.8m in the first quarter of 2019 from $7.7m the year before and achieved positive cash flow.

Stem-cell treatments, then, clearly have huge potential and this is an area that biotech investors should watch carefully since it is likely to lead to blockbuster products in the next few years. However, investing in the mainly early stage companies is risky because almost all the biotechs involved are making losses and promising phase-III clinical trials can fail, causing serious share-price falls. However, a successful phase-III clinical trial can have a very positive effect on a biotech's share price and may also lead to a takeover bid.

My favourite biotechs of the ones mentioned above are Fate Therapeutics (Nasdaq: FATE) and Sangamo Therapeutics (Nasdaq: SGMO), which are the largest, both with Big Pharma collaborators, Sangamo having many more clinical trials. Then there are Mesoblast (Sydney: MSB) with one marketed product, a strong pipeline with three phase-III trials and Big Pharma collaborators; and Vericel (Nasdaq: VCEL), which has one marketed product and came close to profitability in the first quarter.

Highly qualified (BSc PhD CPhys FInstP MIoD) expert in R&D management, business improvement and investment analysis, Dr Mike Tubbs worked for decades on the 'inside' of corporate giants such as Xerox, Battelle and Lucas. Working in the research and development departments, he learnt what became the key to his investing; knowledge which gave him a unique perspective on the stock markets.

Dr Tubbs went on to create the R&D Scorecard which was presented annually to the Department of Trade & Industry and the European Commission. It was a guide for European businesses on how to improve prospects using correctly applied research and development. He has been a contributor to MoneyWeek for many years, with a particular focus on R&D-driven growth companies.

How stem cells are changing the face of medicine

The 2012 breakthrough

Subscribe to MoneyWeek

Sign up to Money Morning

The two stem-cell treatments so far

The potential in umbilical cords

Research is gathering pace

Promising pipelines

How to invest in the theme

How to assess the middle of the market

The drugs that could become bestsellers

The stocks to research now